Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 6159K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JCB Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goncharova, E. Articles by Krymskaya, V. P. Search for Related Content PubMed PubMed Citation Articles by Goncharova, E. Articles by Krymskaya, V. P. Social Bookmarking                            What's this?

TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase

¹ Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104
² Department of Biochemistry, Chandler Medical Center, University of Kentucky, Lexington, KY 40536

Correspondence to Vera P. Krymskaya: krymskay{at}mail.med.upenn.edu

Tuberous sclerosis complex (TSC) 1 and TSC2 are thought to be involved in protein translational regulation and cell growth, and loss of their function is a cause of TSC and lymphangioleiomyomatosis (LAM). However, TSC1 also activates Rho and regulates cell adhesion. We found that TSC2 modulates actin dynamics and cell adhesion and the TSC1-binding domain (TSC2-HBD) is essential for this function of TSC2. Expression of TSC2 or TSC2-HBD in TSC2–/– cells promoted Rac1 activation, inhibition of Rho, stress fiber disassembly, and focal adhesion remodeling. The down-regulation of TSC1 with TSC1 siRNA in TSC2–/– cells activated Rac1 and induced loss of stress fibers. Our data indicate that TSC1 inhibits Rac1 and TSC2 blocks this activity of TSC1. Because TSC1 and TSC2 regulate Rho and Rac1, whose activities are interconnected in a reciprocal fashion, loss of either TSC1 or TSC2 function may result in the deregulation of cell motility and adhesion, which are associated with the pathobiology of TSC and LAM.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., Ramesh, V. (2009). NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth. Mol. Cell. Biol. 29: 4250-4261 [Abstract] [Full Text]  
• Finlay, G. A., Malhowski, A. J., Polizzi, K., Malinowska-Kolodziej, I., Kwiatkowski, D. J. (2009). Renal and liver tumors in Tsc2+/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Molecular Cancer Therapeutics 8: 1799-1807 [Abstract] [Full Text]  
• Campos, S. B., Ashworth, S. L., Wean, S., Hosford, M., Sandoval, R. M., Hallett, M. A., Atkinson, S. J., Molitoris, B. A. (2009). Cytokine-induced F-actin reorganization in endothelial cells involves RhoA activation. Am. J. Physiol. Renal Physiol. 296: F487-F495 [Abstract] [Full Text]  
• McNeill, H., Craig, G. M., Bateman, J. M. (2008). Regulation of Neurogenesis and Epidermal Growth Factor Receptor Signaling by the Insulin Receptor/Target of Rapamycin Pathway in Drosophila. Genetics 179: 843-853 [Abstract] [Full Text]  
• Meikle, L., Pollizzi, K., Egnor, A., Kramvis, I., Lane, H., Sahin, M., Kwiatkowski, D. J. (2008). Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function. J. Neurosci. 28: 5422-5432 [Abstract] [Full Text]  
• Lu, K. H., Wu, W., Dave, B., Slomovitz, B. M., Burke, T. W., Munsell, M. F., Broaddus, R. R., Walker, C. L. (2008). Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma. Clin. Cancer Res. 14: 2543-2550 [Abstract] [Full Text]  
• Goncharova, E. A., Goncharov, D. A., Chisolm, A., Spaits, M. S., Lim, P. N., Cesarone, G., Khavin, I., Tliba, O., Amrani, Y., Panettieri, R. A. Jr., Krymskaya, V. P. (2008). Interferon {beta} Augments Tuberous Sclerosis Complex 2 (TSC2)-Dependent Inhibition of TSC2-Null ELT3 and Human Lymphangioleiomyomatosis-Derived Cell Proliferation. Mol. Pharmacol. 73: 778-788 [Abstract] [Full Text]  
• Krymskaya, V. P. (2008). Smooth Muscle like Cells in Pulmonary Lymphangioleiomyomatosis. Proc Am Thorac Soc 5: 119-126 [Abstract] [Full Text]  
• Finlay, G. A., Malhowski, A. J., Liu, Y., Fanburg, B. L., Kwiatkowski, D. J., Toksoz, D. (2007). Selective Inhibition of Growth of Tuberous Sclerosis Complex 2 Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR/S6 Kinase Activity. Cancer Res. 67: 9878-9886 [Abstract] [Full Text]  
• Meikle, L., Talos, D. M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., Jensen, F. E., Kwiatkowski, D. J. (2007). A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival. J. Neurosci. 27: 5546-5558 [Abstract] [Full Text]  
• Sandsmark, D. K., Zhang, H., Hegedus, B., Pelletier, C. L., Weber, J. D., Gutmann, D. H. (2007). Nucleophosmin Mediates Mammalian Target of Rapamycin-Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes. Cancer Res. 67: 4790-4799 [Abstract] [Full Text]  
• Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M. P., Russell, R. G., Mueller, S. C., Ojeifo, J., Chen, W. S., Hay, N., Pestell, R. G. (2007). Akt1 governs breast cancer progression in vivo. Proc. Natl. Acad. Sci. USA 104: 7438-7443 [Abstract] [Full Text]  
• Juvet, S. C., McCormack, F. X., Kwiatkowski, D. J., Downey, G. P. (2007). Molecular Pathogenesis of Lymphangioleiomyomatosis: Lessons Learned from Orphans. Am. J. Respir. Cell Mol. Bio. 36: 398-408 [Abstract] [Full Text]  
• York, B., Lou, D., Noonan, D. J. (2006). Tuberin Nuclear Localization Can Be Regulated by Phosphorylation of Its Carboxyl Terminus. Mol Cancer Res 4: 885-897 [Abstract] [Full Text]  
• Goncharova, E. A., Goncharov, D. A., Spaits, M., Noonan, D. J., Talovskaya, E., Eszterhas, A., Krymskaya, V. P. (2006). Abnormal Growth of Smooth Muscle-Like Cells in Lymphangioleiomyomatosis: Role for Tumor Suppressor TSC2. Am. J. Respir. Cell Mol. Bio. 34: 561-572 [Abstract] [Full Text]  
• Goncharova, E. A., Goncharov, D. A., Lim, P. N., Noonan, D., Krymskaya, V. P. (2006). Modulation of Cell Migration and Invasiveness by Tumor Suppressor TSC2 in Lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Bio. 34: 473-480 [Abstract] [Full Text]  
• Liu, H., Radisky, D. C., Nelson, C. M., Zhang, H., Fata, J. E., Roth, R. A., Bissell, M. J. (2006). Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2.. Proc. Natl. Acad. Sci. USA 103: 4134-4139 [Abstract] [Full Text]  
• Lesma, E., Grande, V., Carelli, S., Brancaccio, D., Canevini, M. P., Alfano, R. M., Coggi, G., Di Giulio, A. M., Gorio, A. (2005). Isolation and Growth of Smooth Muscle-Like Cells Derived from Tuberous Sclerosis Complex-2 Human Renal Angiomyolipoma: Epidermal Growth Factor Is the Required Growth Factor. Am. J. Pathol. 167: 1093-1103 [Abstract] [Full Text]  
• Gau, C.-L., Kato-Stankiewicz, J., Jiang, C., Miyamoto, S., Guo, L., Tamanoi, F. (2005). Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Molecular Cancer Therapeutics 4: 918-926 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents